Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYI 2074

Next Previous
X
Search
Drug Profile

SYI 2074

Alternative Names: ALT-2074; BXT 51072; SYN-2074

Latest Information Update: 08 Apr 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OXIS Therapeutics
  • Developer OXIS Therapeutics; Synvista Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cell adhesion molecule inhibitors; Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Asthma; Chronic obstructive pulmonary disease; Hepatitis; Plaque psoriasis; Respiratory distress syndrome; Septic shock; Ulcerative colitis

Most Recent Events

  • 28 Jan 2009 Discontinued - Phase-II for Plaque psoriasis in Israel (Topical)
  • 15 Dec 2008 Phase-II clinical trials in Plaque psoriasis in Israel (Topical)
  • 29 Sep 2008 Israeli Ministry of Health grants approval for a phase I/II trial of SYI 2074 in Plaque psoriasis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top